Google Patents Wasn’t Built for Pharma — Here’s What It Misses Every Time You Search a Drug Name
The Short Answer Google Patents is a free document index built for general-purpose prior art search. It has no connection […]
No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It.
US Patent 11,530,197 B2 covers the compound that became rentosertib, the TNIK inhibitor that Insilico Medicine says is the first
No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It. Read Post »
The Free Patent Database Costing Your Team Thousands an Hour in Manual Cross-Referencing
The FDA Orange Book does not link to the USPTO’s patent database. The USPTO’s patent database does not link to
The Free Patent Database Costing Your Team Thousands an Hour in Manual Cross-Referencing Read Post »
Why a Spreadsheet of Expiration Dates Isn’t a Strategy — It’s a Liability With a Due Date
Eliquis has four expiration dates. Not one, not two. Four. The composition-of-matter patent covering apixaban was originally set to expire
The Analyst Report That Took Three Weeks Should Have Taken Three Hours — Here’s the Bottleneck
A comprehensive freedom-to-operate analysis for a pharmaceutical asset takes four to twelve weeks and costs $50,000 to $200,000 in legal
Why “We’ll Catch It in the Quarterly Review” Is How Companies Miss NCE-1 Dates Every Year
On September 9, 2026, Bristol-Myers Squibb’s five-year new chemical entity (NCE) exclusivity for Sotyktu (deucravacitinib) reaches its four-year mark. That
Stop Searching Patents. Start Asking Them Questions.
On October 8, 2025, the U.S. Patent and Trademark Office quietly admitted something the patent search industry had been saying
Stop Searching Patents. Start Asking Them Questions. Read Post »
Your Competitive Intelligence Team Is Still Reading PACER by Hand. Here Is the Cost in Reaction Time.
The Short Answer A pharmaceutical patent lawsuit becomes public the moment it is entered on a federal docket. Nobody has
The Three-Clock Problem: Why Patent Expiration Dates Don’t Predict Generic Launch Dates
Eight of Teva’s nine Copaxone patents expired in May 2014. The first FDA-approved generic, Sandoz’s Glatopa, didn’t reach a pharmacy
The Three-Clock Problem: Why Patent Expiration Dates Don’t Predict Generic Launch Dates Read Post »
